10x Genomics delivered a solid third quarter, with revenue reaching $149.0 million, a 2% sequential increase excluding one-time license and royalty revenue from the prior quarter. The company reported a net loss of $27.5 million, an improvement from the $35.8 million net loss in the same period last year. Gross margin decreased to 67% due to product mix and higher inventory write-downs, while operating expenses saw a 10% reduction.
Revenue for Q3 2025 was $149.0 million, a 2% decrease from Q3 2024, primarily due to lower instrument revenue.
Net loss improved to $27.5 million in Q3 2025, compared to a net loss of $35.8 million in Q3 2024.
Gross margin was 67% in Q3 2025, down from 70% in the prior year period, influenced by product mix and inventory write-downs.
Operating expenses decreased by 10% to $132.5 million, driven by lower personnel and legal expenses.
10x Genomics expects fourth quarter 2025 revenue to be in the range of $154 million to $158 million, representing a 6% decline from the corresponding prior year period and 5% growth sequentially at the midpoint.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance